| Entry |
|
|---|
| Name |
Oblimersen sodium (USAN);
Genasense (TN) |
|---|
| Formula |
C172H204N62O91P17S17. 17Na
|
|---|
| Exact mass |
6054.2294
|
|---|
| Mol weight |
6058.35
|
|---|
| Remark |
|
|---|
| Efficacy |
Antineoplastic, Translation inhibitor, Bcl-2 inhibitor |
|---|
| Type |
Antisense oligonucleotide |
|---|
| Comment |
Treatment of cancer and rheumatological diseases
|
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XX Other antineoplastic agents
L01XX36 Oblimersen
D05216 Oblimersen sodium (USAN)
Target-based classification of drugs [BR:br08310]
Not elsewhere classified
Cellular process
Apoptosis
BCL2
D05216 Oblimersen sodium (USAN)
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
